Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells
- 1 December 2005
- journal article
- research article
- Published by Wiley in NMR in Biomedicine
- Vol. 18 (8) , 553-559
- https://doi.org/10.1002/nbm.991
Abstract
Two FDA-approved agents, ferumoxides (Feridex), a suspension of superparamagnetic iron oxide (SPIO) nanoparticles and protamine sulfate, a drug used to reverse heparin anticoagulation, can be complexed and used to label cells magnetically ex vivo. Labeling stem cells with ferumoxides-protamine sulfate (FePro) complexes allows for non-invasive monitoring by MRI. However, in order for stem cell trials or therapies to be effective, this labeling technique must not inhibit the ability of cells to differentiate. In this study, we examined the effect of FePro labeling on stem cell differentiation. Viability, phenotypic expression and differential capacity of FePro labeled CD34 + hematopoietic stem cells (HSC) and mesenchymal stem cells (MSC) were compared with unlabeled control cells. Colony-forming unit (CFU) assays showed that the capacity to differentiate was equivalent for labeled and unlabeled HSC. Furthermore, labeling did not alter expression of surface phenotypic markers (CD34, CD31, CXCR4, CD20, CD3 and CD14) on HSC, as measured by flow cytometry. SDF-1-induced HSC migration and HSC differentiation to dendritic cells were also unaffected by FePro labeling. Both FePro-labeled and unlabeled MSC were cultured in chondrogenesis-inducing conditions. Alcian blue staining for proteoglycans revealed similar chondrogenic differentiation for both FePro-labeled and unlabeled cells. Furthermore, collagen X proteins, indicators of cartilage formation, were detected at similar levels in both labeled and unlabeled cell pellets. Prussian blue staining confirmed that cells in labeled pellets contained iron oxide, whereas cells in unlabeled pellets did not. It is concluded that FePro labeling does not alter the function or differentiation capacity of HSC and MSC. These data increase confidence that MRI studies of FePro-labeled HSC or MSC will provide an accurate representation of in vivo trafficking of unlabeled cells.Keywords
This publication has 25 references indexed in Scilit:
- In Vivo Trafficking and Targeted Delivery of Magnetically Labeled Stem CellsHuman Gene Therapy, 2004
- Published by Wiley ,2004
- Characterization of Biophysical and Metabolic Properties of Cells Labeled with Superparamagnetic Iron Oxide Nanoparticles and Transfection Agent for Cellular MR ImagingRadiology, 2003
- Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniquesTransplantation, 2003
- Serial Cardiac Magnetic Resonance Imaging of Injected Mesenchymal Stem CellsCirculation, 2003
- Clinically Applicable Labeling of Mammalian and Stem Cells by Combining Superparamagnetic Iron Oxides and Transfection AgentsRadiology, 2003
- In Vivo Magnetic Resonance Imaging of Mesenchymal Stem Cells in Myocardial InfarctionCirculation, 2003
- Monitoring of implanted stem cell migration in vivo : A highly resolved in vivo magnetic resonance imaging investigation of experimental stroke in ratProceedings of the National Academy of Sciences, 2002
- MRI of insulitis in autoimmune diabetesMagnetic Resonance in Medicine, 2002
- Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cellsNature Biotechnology, 2001